Open clinical comparison dataset

15 results.
Every caveat attached.

Name: Weight-Loss Drug Trial Results Comparison Dataset
Creator: Peptide Local Editorial Desk
Published: 2026-07-21
License: https://peptidelocal.com/data/license

Download a normalized, source-linked table of selected Retatrutide, CagriSema, MariTide, Cagrilintide, Zenagamtide/Amycretin, Survodutide, VK2735, and other weight-loss drug trial observations. The dataset preserves weeks, phase, route, dose, population, comparator, result basis, estimand, current study design, registry status, and regulatory status.

Selected observations, not a league table.A source-linked orientation dataset of selected reported mean body-weight results from separate clinical trials. Differences in population, duration, dose, route, phase, estimand, adherence assumptions, rescue treatment, missing-data handling, comparator response, and source maturity prevent a cross-trial efficacy or safety ranking. A chart position is not a treatment recommendation, approval, individual prediction, or head-to-head result.

Open interactive chartFilter by phase, route, duration, and result basis Download CSVOne row per selected trial observation Download JSONNested aliases, statistics, and methodology

Selection and normalization method

One observation per trial and formulation.

We selected one obesity or overweight trial observation for each named program. VK2735 has separate rows because its oral and injected results came from separate trials. CagriSema and cagrilintide have separate rows because REDEFINE 1 randomized them as different interventions.

The primary result remains on the source's own statistical basis. Enicepatide is labelled as a placebo-adjusted difference. Most other values are active-arm means. Treatment-policy, treatment-regimen, or alternate efficacy analyses remain attached to the same trial record instead of being counted as new studies.

Values are stored as positive reduction magnitudes for readability. Mazdutide's placebo group had a reported 0.30% mean gain, so its comparator field is negative. No row is converted into a weekly rate, standardized effect, or cross-trial rank.

ClinicalTrials.gov design fields are stored as a separate registry snapshot. Registry enrollment can differ from the participant basis in a publication or sponsor result because the records can represent different dates, cohorts, or analysis sets.

Complete HTML release

15 source-linked observations.

This table is the indexable human-readable release. CSV and JSON carry the same records for reuse, while the interactive chart provides a visual exploration layer.

Program	Trial and duration	Study design	Reported result	Comparator	Analysis	Population	Status	Source
MariTidemaridebart cafraglutide · AMG 133	Phase 2 dose-ranging studyNCT05669599 · Phase 2 · 52 weeks · Monthly injection	Randomized · Parallel assignmentQuadruple masking · 592 actual enrollment · Completed	19.9% mean reductionUpper reported dose-group result	2.6% mean reduction	Active-arm meanEfficacy estimand, upper end of the reported dose-group rangeAlternate: 16.2% mean reduction · Treatment-policy estimand, upper end of the reported dose-group range	Adults with obesity or overweight, without type 2 diabetes465 participants · Cohort A; 592 adults were enrolled across cohorts A and B	Investigational; not FDA approved	AmgenSponsor topline report · June 23, 2025
ZenagamtideAmycretin · NNC0487-0111	First-in-human oral multiple-dose cohortNCT05369390 · Phase 1 · 12 weeks · Daily oral	Randomized · Sequential assignmentQuadruple masking · 144 actual enrollment · Completed	13.1% mean reductionOral dose reported in the 12-week cohort	1.1% mean reduction	Active-arm meanSponsor-reported exploratory Phase 1 mean	Adults with obesity or overweight16 participants · Active oral cohort only	Investigational; not FDA approved	Novo NordiskSponsor presentation · March 2024
CagriSemacagrilintide plus semaglutide · REDEFINE 1	REDEFINE 1NCT05567796 · Phase 3 · 68 weeks · Weekly injection	Randomized · Parallel assignmentQuadruple masking · 3,400 estimated enrollment · Active, not recruiting	22.7% mean reductionCagrilintide 2.4 mg plus semaglutide 2.4 mg, flexible dosing	2.3% mean reduction	Active-arm meanTrial-product estimandAlternate: 20.4% mean reduction · Treatment-policy estimand	Adults with obesity or overweight and at least one complication3,417 participants · Total randomized trial population across four arms	FDA application under review; not yet approved	PubMed / New England Journal of MedicinePeer-reviewed publication · June 22, 2025
CagrilintideAM833 · NNC0174-0833	REDEFINE 1 monotherapy armNCT05567796 · Phase 3 · 68 weeks · Weekly injection	Randomized · Parallel assignmentQuadruple masking · 3,400 estimated enrollment · Active, not recruiting	11.8% mean reductionCagrilintide 2.4 mg, flexible dosing	2.3% mean reduction	Active-arm meanTrial-product estimandAlternate: 11.5% mean reduction · Treatment-policy estimand	Adults with obesity or overweight and at least one complication3,417 participants · Total randomized trial population; this row represents the cagrilintide arm	Investigational; not FDA approved	PubMed / New England Journal of MedicinePeer-reviewed publication · June 22, 2025
RetatrutideLY3437943 · triple agonist · reta	TRIUMPH-1NCT05929066 · Phase 3 · 80 weeks · Weekly injection	Randomized · Parallel assignmentDouble masking · 2,335 actual enrollment · Completed	28.3% mean reduction12 mg	2.2% mean reduction	Active-arm meanEfficacy estimandAlternate: 25% mean reduction · Treatment-regimen estimand	Adults with obesity or overweight and at least one complication2,339 participants · Total randomized master-trial population	Investigational; not FDA approved	Eli Lilly and CompanySponsor topline report · May 21, 2026
MazdutideIBI362 · LY3305677	GLORY-1NCT05607680 · Phase 3 · 48 weeks · Weekly injection	Randomized · Parallel assignmentTriple masking · 610 actual enrollment · Completed	14.01% mean reduction6 mg	0.3% mean gain	Active-arm meanPeer-reviewed trial mean	Chinese adults with obesity or overweight610 participants · Total randomized trial population	Approved in China for chronic weight management; not FDA approved	New England Journal of MedicinePeer-reviewed publication · May 28, 2025
MazdutideIBI362 · LY3305677	GLORY-2NCT06164873 · Phase 3 · 60 weeks · Weekly injection	Randomized · Parallel assignmentQuadruple masking · 462 actual enrollment · Active, not recruiting	16.65% mean reduction9 mg	1.5% mean reduction	Active-arm meanPeer-reviewed analysis of participants receiving at least one dose	Chinese adults with moderate to severe obesity, with or without type 2 diabetes461 participants · Participants receiving at least one dose; the registry records 462 randomized participants	9 mg application under NMPA review in China; not FDA approved	PubMed / JAMAPeer-reviewed publication · June 8, 2026
EnicepatideCT-388 · RO7795068 · RG6640	CT388-103NCT06525935 · Phase 2 · 48 weeks · Weekly injection	Randomized · Parallel assignmentDouble masking · 469 actual enrollment · Completed	22.5% mean reduction24 mg, highest tested dose	Not separately reported	Placebo-adjusted differencePlacebo-adjusted efficacy estimateAlternate: 18.3% mean reduction · Placebo-adjusted treatment-regimen estimate	Adults with obesity or overweight and at least one complication469 participants · Total randomized dose-finding trial population	Investigational; not FDA approved	RocheSponsor topline report · January 27, 2026
EloralintideLY3841136 · selective amylin receptor agonist	Phase 2 obesity trialNCT06230523 · Phase 2 · 48 weeks · Weekly injection	Randomized · Parallel assignmentDouble masking · 263 actual enrollment · Completed	20% mean reduction9 mg and 6-to-9 mg strategies	0.4% mean reduction	Active-arm meanEfficacy estimand, rounded result for two dose strategies	Adults with obesity or overweight and at least one complication263 participants · Total randomized trial population	Investigational; not FDA approved	PubMed / The LancetPeer-reviewed publication · November 7, 2025
PetrelintideZP8396 · long-acting amylin analogue	ZUPREME-1NCT06662539 · Phase 2 · 42 weeks · Weekly injection	Randomized · Parallel assignmentDouble masking · 493 actual enrollment · Completed	10.7% mean reductionUpper reported dose-group result	1.7% mean reduction	Active-arm meanEfficacy estimand, upper end of five dose-group estimates	Adults with obesity or overweight and weight-related complications493 participants · Total randomized trial population	Investigational; not FDA approved	RocheSponsor topline report · March 5, 2026
SurvodutideBI 456906 · GLP-1/glucagon dual agonist	SYNCHRONIZE-1NCT06066515 · Phase 3 · 76 weeks · Weekly injection	Randomized · Parallel assignmentQuadruple masking · 726 actual enrollment · Completed	16.6% mean reduction6 mg, upper reported result	3.2% mean reduction	Active-arm meanEfficacy estimand, upper reported resultAlternate: 13% mean reduction · Treatment-regimen estimand	Adults with obesity or overweight726 participants · Actual enrollment in the completed trial record	Investigational; not FDA approved	PubMed / New England Journal of MedicinePeer-reviewed publication · June 7, 2026
VK2735 injectionViking VK2735 · VENTURE injectable	VENTURENCT06068946 · Phase 2 · 13 weeks · Weekly injection	Randomized · Parallel assignmentTriple masking · 176 actual enrollment · Completed	14.7% mean reduction15 mg	1.7% mean reduction	Active-arm meanPeer-reviewed 13-week mean	Adults with obesity or overweight and at least one complication176 participants · Total randomized trial population	Investigational; not FDA approved	PubMed / ObesityPeer-reviewed publication · January 8, 2026
VK2735 oralOral VK2735 · VENTURE-Oral	VENTURE-OralNCT06828055 · Phase 2 · 13 weeks · Daily oral	Randomized · Parallel assignmentTriple masking · 280 actual enrollment · Completed	12.2% mean reduction120 mg	1.3% mean reduction	Active-arm meanSponsor-reported 13-week mean	Adults with obesity or overweight and at least one complication280 participants · Total randomized trial population	Investigational; not FDA approved	Viking TherapeuticsSponsor topline report · May 12, 2026
EcnoglutideXW003 · Sciwind ecnoglutide · 埃诺格鲁肽	SLIMMERNCT05813795 · Phase 3 · 48 weeks · Weekly injection	Randomized · Parallel assignmentTriple masking · 664 actual enrollment · Completed	15.4% mean reduction2.4 mg	0.3% mean reduction	Active-arm meanTreatment-policy estimandAlternate: 15.1% mean reduction · Placebo-adjusted difference	Chinese adults with obesity or overweight664 participants · Total randomized trial population	Approved in China for chronic weight management; not FDA approved	Sciwind BiosciencesSponsor topline report · March 6, 2026
PemvidutideALT-801 · balanced GLP-1/glucagon dual agonist	MOMENTUMNCT05295875 · Phase 2 · 48 weeks · Weekly injection	Randomized · Parallel assignmentDouble masking · 391 actual enrollment · Completed	15.6% mean reduction2.4 mg	2.2% mean reduction	Active-arm meanSponsor-reported 48-week mean	Adults with obesity, or overweight plus a comorbidity391 participants · Total randomized trial population	Investigational; not FDA approved	AltimmuneSponsor topline report · June 23, 2024

Data dictionary

Fields that prevent a false comparison.

reported_mean_reduction_pct: The source-reported active-arm mean reduction magnitude, except where result_basis explicitly says placebo-adjusted difference.
comparator_mean_reduction_pct: The comparator's reported mean reduction magnitude. A negative value means the source reported mean weight gain.
result_basis: Whether the plotted number is an active-arm mean or a placebo-adjusted difference.
estimand: The source's analysis label or the closest precise description preserved from the record.
alternate_mean_reduction_pct: A second analysis of the same trial, such as treatment-policy or treatment-regimen, not a separate study.
participants: The relevant active cohort or total randomized population, with participants_note explaining which denominator is used.
registry_enrollment: The enrollment count in the current ClinicalTrials.gov study record. It remains separate from the outcome source's analyzed cohort or randomized population.
registry_enrollment_type: Whether ClinicalTrials.gov labels the current enrollment count as actual or estimated.
registry_status: The current ClinicalTrials.gov study status. It describes the trial, not approval or legal availability of the drug.
study_allocation: The assignment method recorded by ClinicalTrials.gov, such as randomized.
study_intervention_model: The study-arm model recorded by ClinicalTrials.gov, such as parallel or sequential assignment.
study_masking: The masking level in the current registry record. masked_parties names the roles that were masked.
regulatory_status: A jurisdiction-specific status snapshot. China approval never implies FDA approval or worldwide availability.
source_kind: Peer-reviewed publication, sponsor topline report, or sponsor presentation.

Citation and corrections

Cite the landing page so the boundary travels.

Suggested citation: Peptide Local Editorial Desk. “Weight-Loss Drug Trial Results Comparison Dataset.” Version 2026-07-21. https://peptidelocal.com/data/weight-loss-drug-trial-results.

Evidence checked July 21, 2026. Sponsor topline records can later be supplemented or revised by conference presentations, peer-reviewed publications, registry updates, and regulatory decisions.

Read the editorial method Submit a source correction